← Eichor
Condition: Temozolomide Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Temozolomide

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

CapTemY90 for Grade 2/3 NET Liver Metastases
Phase 2 · 4 location(s) · Abramson Cancer Center at Penn Medicine · NCT04339036Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma
Phase 2 · 1 location(s) · Tianjin Medical University General Hospital · NCT06327451Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
Phase 1 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT05083754NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Phase 2 · 13 location(s) · New Approaches to Neuroblastoma Therapy Consortium · NCT06450041Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared
Phase 3 · 1 location(s) · Northwell Health · NCT052712405G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
Phase 1/Phase 2 · 3 location(s) · Institute of Cancer Research, United Kingdom · NCT066302605G-PEARL: Paxalisib in Malignant Brain Tumours
Phase 1/Phase 2 · 1 location(s) · Institute of Cancer Research, United Kingdom · NCT07391215A Phase 2 Study of HX301 in Patients with High-grade Giloma
Phase 1/Phase 2 · 1 location(s) · Hangzhou Hanx Biopharmaceuticals, Ltd. · NCT06703255Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma
Phase 2 · 1 location(s) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRS · NCT04523688NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Phase 1/Phase 2 · 1 location(s) · Nationwide Children's Hospital · NCT04211675hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
Phase 2 · 1 location(s) · Leland Metheny · NCT05052957A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primar
Phase 1/Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06556199ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
Phase 2 · 22 location(s) · University of Birmingham · NCT05629702Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Di
Phase 2 · 11 location(s) · Alpheus Medical, Inc. · NCT07225621A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma
Phase 1/Phase 2 · 3 location(s) · Novelwise Pharmaceutical Corporation · NCT07569042Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Phase 2 · 22 location(s) · Black Diamond Therapeutics, Inc. · NCT07326566NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma
Phase 1/Phase 2 · 4 location(s) · Novelwise Pharmaceutical Corporation · NCT06012695Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors
Phase 1/Phase 2 · 12 location(s) · Centre Leon Berard · NCT07243470Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
Phase 2 · 2 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06617923Study of Olutasidenib and Temozolomide in HGG
Phase 2 · 20 location(s) · Rigel Pharmaceuticals · NCT06161974A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ
NA · 1 location(s) · Ruijin Hospital · NCT07191431Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Phase 2 · 5 location(s) · Dwight Owen · NCT04919382IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma
Phase 3 · 20 location(s) · Ono Pharmaceutical Co., Ltd. · NCT07104032Safety and Effectiveness Evaluation of Temozolomide (Amitzo, NanoAlvand) in Patients With Grade III and IV Glioma Tumors
Phase N/A · 1 location(s) · NanoAlvand · NCT07675070Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Phase 3 · 20 location(s) · Vastra Gotaland Region · NCT06419946Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas
Phase 2 · 1 location(s) · Beijing Sanbo Brain Hospital · NCT04267978The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma
NA · 2 location(s) · Ottawa Hospital Research Institute · NCT06850766PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Phase 1/Phase 2 · 7 location(s) · Theodore Laetsch · NCT06721689Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
Phase 1 · 1 location(s) · Northwestern University · NCT06410248Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
NA · 1 location(s) · Zhejiang Cancer Hospital · NCT06832267
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.